☆ 4.7 Meeting Abstract

Time to response, duration of response, and patient-reported outcomes (PROs) with daratumumab (DARA) plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): Subgroup analysis of the phase 3 MAIA study.

JOURNAL OF CLINICAL ONCOLOGY (2022)

主要评分表示论文的整体质量水平。次要评分独立反映论文的优点或缺点。

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now